Authors:

Fischer Mahir, PhD

Institute of Spatial Planning, University of Natural Resources and Life Sciences, Vienna, Austria

Abstract:

Hepatitis C virus (HCV) infection is presently one among the most causes of liver disease and malignant hepatoma (HCC) at a worldwide level. Recently, a brand new generation of direct-acting antiviral agents (DAAs) has entered the HCV treatment landscape, providing imposingly high rates of sustained medicine response (SVR), associate degreed is anticipated to steer to an ultimate decrease in HCV-related liver disease, liver transplantation and mortality. However, throughout the primary years of their use, many studies reportable a potential correlation between DAA treatment associate degreed an redoubled risk of HCC. Following the publication of larger prospective studies, the chance of American state novo HCC incidence has clearly been tried to be lower when the accomplishment of international intelligence agency, notwithstanding antiviral treatment. On the opposite hand, the chance of HCC return following treatment with DAAs is debatable; existing knowledge stay debatable, presumably owing to the shortage of enormous, handy cohorts with a lot of homogenized patient populations. With relation to the pathophysiology behind the higher than observations, particularly in patients with previous HCC history, HCC development might presumably be favored by the changes within the medicine surroundings and also the completely different cellular behavior when obliteration of HCV infection with DAA treatment.

Keywords:
Hepatocellular carcinoma, direct acting antivirals, hepatitis C, cirrhosis, interferon.

Citation:

Fischer Mahir, PhD. Evidence and pathophysiological concerns regarding the impact of direct-acting antiviral medicines on the development of hepatocellular carcinoma Japanese Journal of Gastroenterology 2022.